Includes Total Omnipod Revenue Growth of 33%. Insulet Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Year-Over-Year ... INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) March 31, 2019. The dynamics of net revenue of Insulet Corporation rose. The change amounted to 14 979 000 $. 2015 2016 2017 2018 2019 5-year trend; Sales/Revenue 263.89M: 366.99M: 463.77M: 563.82M Insulet's revenue is the ranked 7th among it's top 10 competitors.

Includes Total Omnipod Revenue Growth of 33% ACTON, Mass. Information about net revenue is taken from open sources. First Quarter Financial Highlights:

See how it's improving lives with better adherence and seamless delivery. ASSETS: Cash, cash equivalents and … ACTON, Mass.--(BUSINESS WIRE)--Aug. 5, 2019-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months ended June 30, 2019. Insulet Corporation total revenue, net income and dynamics of changes in US dollar today. All values USD millions. Insulet Corporation has annual revenue of $309.7M, total funding of N/A, has 1234 employees and grew their employee count by 20% last year. Automate injectable drug delivery with the customizable OmniPod by Insulet. The top 10 competitors average 7.1B. --(BUSINESS WIRE)--May 7, … Fiscal year is January-December.

December 31, 2018. Net revenue Insulet Corporation is now 192 115 000 $.

Over the last three quarters, Insulet's revenue has grown by 38.1%. ACTON, Mass.--(BUSINESS WIRE)--May 7, 2020-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months ended March 31, 2020.

Specifically, in Q4 2019's revenue was $244.7M; in Q3 2019, it was $192.1M; in Q2 2019, it was $177.1M.